01

Precision Oncology Small Molecule Therapies

Cancer is a leading cause of death in China and worldwide.  Abbisko has assembled a R&D team with ample experience in characterizing various types of cancers and identifying key genetic drivers of these diseases. Based on these findings, we are driven to discover and develop next generation innovative small molecule therapies to treat patients and improve the quality of their lives.  

02

Immuno-Oncology Small Molecule Therapies

Immuno-oncology (IO) therapies have revolutionized anti-cancer therapies in the past a few years. The drugs can harness the innate power of human immune system to selectively eradicate cancer cells by activating tumor-specific immune response while sparing toxicity on normal cells caused by traditional targeted or chemotherapies. Several therapeutic antibodies against immune checkpoint receptors and ligands, such as PD1, CTL4 and PD-L1, have demonstrated striking and durable clinical responses across many types of tumors and become billion-dollar blockbusters. Abbisko is developing a pipeline of the next-generation small molecule immune modulators to improve efficacy, overcome resistance, reduce side effects, and synergize with first generation IO agents.